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Epidemiologically-related traits may share genetic risk factors and pleiotropic 
analysis could identify individual loci associated with these traits. Because of 
their shared epidemiological associations, we conducted pleiotropic analysis of 
genome-wide association studies of lung cancer (12,160 lung cancer cases and 
16,838 controls) and cardiovascular disease risk factors (blood lipids from 
188,577 subjects, type 2 diabetes from 148,821 subjects, body mass index from 
123,865 subjects, and smoking phenotypes from 74,053 subjects). We found that 
6p22.1 (rs6904596, ZNF184) was associated with both lung cancer (P=5.5x10-6) 
and blood triglycerides (P=1.39x10-5). We replicated the association in 6,097 lung 
cancer cases and 204,657 controls (P=2.4×10-4) and in 71,113 subjects with 
triglycerides data (P=0.011). rs6904596 reached genome-wide significance in  
lung cancer meta-analysis (odds ratio=1.15, Pcombined=5.2x10-9). The large sample 
size provided by the lipid GWAS data and the shared genetic risk factors 
between the two traits contributed to the uncovering of a hitherto unidentified 
genetic locus for lung cancer. 
 
 
 
Genetic heritability of lung cancer is estimated to be 14% [1], but only a few genetic 
risk loci have been identified to date in genome-wide association studies (GWAS) of 
lung cancer in Europeans [2]. Epidemiological studies have shown associations 
between lung cancer and cardiovascular disease (CVD) risk factors related to the 
metabolic syndrome [3,4]. There is also substantial evidence that lipid metabolism 
and innate immunity evolved from common pathways and consequently genes that 
influence lipid traits may also influence inflammation and subsequent cancer 
development [5-7]. Lung cancer is also well-known to be strongly associated with 
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tobacco smoking. Predicated on the hypothesis that investigating shared genetic risk 
factors across these traits could enhance the possibility to identify new genetic loci for 
lung cancer, we used quantile-quantile (Q-Q) plots [8] (Online Methods) to assess 
potential polygenic enrichment of SNPs associated with lung cancer given association 
with each CVD risk factor or smoking phenotypes (Figure 1 and Supplementary 
Figure 1). 
 
The analysis was based on the TRICL consortium meta-analysis of lung cancer 
GWAS, including 12,160 lung cancer cases and 16,838 controls [2] (Supplementary 
Table 1); the meta-analysis data of blood lipids from the Global Lipids Genetics 
Consortium (GLGC, including genetic association with triglycerides (TG), and high 
and low density lipoproteins-cholesterol (HDL-C and LDL-C)) from 188,577 subjects 
[9], of Type 2 diabetes (T2D) from 148,821 subjects [10] and of body mass index 
(BMI) from 123,865 subjects [11] ; and the meta-analysis of cigarettes per day (CPD) 
and never vs. ever smoking data from the Tobacco, Alcohol and Genetics (TAG) 
consortium, including 74,053 subjects (Supplementary Table 2). The 
Supplementary Materials (available online) contain additional details on the 
contributing studies, statistical analyses and functional tests. 
 
The Q-Q plots show enrichment between lung cancer and LDL-C and between lung 
cancer and TG blood lipid traits across multiple p-value thresholds up to 10-5 (Figure 
1A-B) verified by an adaptive permutation procedure (Supplementary Table 3). In 
contrast, we observed no significant enrichment (P<0.001) between lung cancer and 
HDL, BMI, T2D or smoking phenotypes (the analysis of smoking excluded the SNP 
markers mapping to chr15:78,686,690-79,231,478, which are known to be 
associated  with  lung  cancer  and  smoking  [12-13]   (Supplementary   Table      3, 
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Supplementary Figure 1). Thus we excluded these traits from further analysis. 
 
Cross-phenotype associated loci between lung cancer and TG and between  lung 
cancer and LDL-C were assessed by conjunction false discovery rate (FDR) [8] 
(Supplementary Materials). Because controlling FDR is heavily affected by the 
number of identified SNPs, we pruned SNPs in linkage disequilibrium (LD) (r2>0.8) 
and excluded the major histocompatibility complex (MHC) (genomic position (hg  
19): chr6:29,528,318-33,373,649 [14]), which harbors established lung cancer 
susceptibility SNPs and is known for long range LD. By controlling conjunction  
FDR, we identified one genetic locus at 6p22.1, rs6904596, A>G, Minor Allele 
Frequency in Caucasians=0.094, associated with both lung cancer and blood 
triglycerides (conjunction FDR=0.0124; P=5.5x10-6 for lung cancer; P=1.39x10-5 for 
TG (This locus and additional genetic loci shared between lung cancer and lipid traits 
are shown in Supplementary Table 4 and Supplementary Figures 2-6). This locus 
remained significant also using different thresholds for pruning SNPs in LD 
(Supplementary Table 5). 
We tested this SNP for replication in 6,097 lung cancer cases and 204,657 controls 
from deCODE, Harvard, Holland and Spain (Supplementary Table 6). This locus 
was replicated (Preplication=2.4×10
-4) and attained genome-wide significance for lung 
cancer risk in the meta-analysis of discovery and replication data (two-sided 
Pcombined=5.2x10
-9, Pheterogeneity=0.91, Table 1). This SNP was also replicated in the 
association with TG in 71,113 independent samples from deCODE and Holland (two- 
sided P=0.011, Pcombined=1.34 x 10
-6, Table 1). 
The SNP association with lung cancer was mostly driven by the squamous cell 
carcinoma subtype (P=2.8x10-5) and not adenocarcinoma (P=0.06,     Supplementary 
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Table 7). 
 
rs6904596 localizes to 6p22.1 (27,491,299 bp; hg19) and lies 50kb 5' of Zinc Finger 
Protein 184 (ZNF184). It shows expression-QTL in lung tissue [15] with HLA-DRB3 
(β=-6.79, P=1.10x10-11). Additionally, rs7749305, located on chr6:27,446,566 (r2=1 
with rs6904596 in HapMap 3 of Caucasian populations), shows suggestive regulatory 
functions. This SNP showed the strongest association with lung cancer, but was not 
genotyped in the Global Lipid Consortium GWAS. It lies within a DNaseI 
hypersensitive region in small airway epithelial cells (SAEC) and A549 
adenocarcinoma cells (ENCODE) and lies in a region hypomethylated in primary 
Alveolar Epithelial Cells (AEC) from our laboratory (Supplementary Figure 7). 
rs7749305 alternate allele C appears to create ATF3 and HIF1A binding sites. Similar 
findings are evident in adipocytes (ENCODE), extending the pleiotropic association 
between lung cancer and lipid traits to their function in respective tissue types. 
 
 
Our study emphasizes that pleiotropic analysis of GWAS data of epidemiologically- 
related traits can uncover hitherto unidentified genetic associations. Moreover, some 
GWAS of quantitative traits may be much larger than disease specific GWAS (like 
in the case of CVD risk factors vs. lung cancer), and thus may improve the 
likelihood to identify new loci for the disease with the smaller sample size. 
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Table 1.   Association of rs6904596 at 6p22.1 with both lung cancer risk and blood triglycerides’ levels 
 
 
 
Study 
Lung cancer 
Cases/ 
Controls 
 
OR 
 
95% CI 
 
P-value 
  
Study 
Triglycerides 
Individuals 
 
𝜷𝜷 
 
95% CI 
 
P-value 
TRICL 12160/16838 1.15 (1.08,1.21) 5.50 x 10-6  GLGC 188577 0.0244 (0.013,0.035) 1.39 x 10-5 
Replication 6097/204657 1.16 (1.07,1.25) 2.4 x 10-4  Replication 71113 0.0290 (0.006,0.051) 1.14 x 10-2 
deCODE 3865/196658 1.17 (1.06,1.30) 3.05 x 10-3  deCODE 66027 0.0200 (-0.004,0.044) 0.10 
Harvard 984/ 970 1.18 (0.93,1.50) 0.171  Holland 5086 0.0891 (0.027,0.151) 5.12 x 10-3 
Holland 687/ 5158 1.15 (0.96,1.37) 0.119       
Spain 561/ 1871 1.10 (0.88,1.37) 0.40  Combined 259690 0.0253 (0.015,0.035) 1.34 x 10-6 
Combined 18257/ 221495 1.15 (1.10,1.21) 5.2 x 10-9       
PQ- 
heterogeneity* 
   
0.92 0.23 
 
* Heterogeneity of effect size across studies was evaluated using the Cochran’s Q statistic 
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 Figures 
 
 
 
 
Figure 1. Conditional Q-Q plots: LuCa | CVD factors (TG and LDL-C). 
‘Conditional Q-Q plot’ of theoretical vs empirical -log10 p-values (corrected for 
genomic control 𝜆𝜆) in lung cancer (LuCa) below the standard GWAS threshold of 
- log10 p-values equal to 7.3 (equals p-values above 5 x 10-8) as a function of 
significance of association with (A) triglycerides (TG) and (B) low-density 
lipoprotein (LDL-C) at the level of p < 1, p <0.1, p < 0.01, p < 0.001, p<0.0001, 
p<0.00001 respectively. Dotted lines indicate the theoretical line in case of no 
association. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Supplementary Material 
 
Supplementary Methods 
 
 
Data and contributing studies 
Input for the genetic epidemiology framework is summary statistics of genome-wide 
association studies (GWAS). Summary statistics on lung cancer were provided by the TRICL 
consortium (1) and were generated from a meta-analysis of 12,160 lung cancer cases and 
16,838 controls. Further details on the sub-studies contributing to the meta-analysis are given 
in Supplementary Table 1. The histology-specific analyses were based on 3,718 
adenocarcinoma (AD) cases and 3,422 squamous cell carcinoma (SQ) cases from the same 
TRICL consortium.  
 Data for the metabolic CVD risk factors was generated from meta-analyses of LDL, 
HDL, and TG (2), BMI (3), and T2D (4). Information on smoking behavior was measured by 
cigarettes per day (CPD) and never vs. ever smoking (SMOKER) in a large meta-analysis (5). 
For more details on these studies we refer to Supplementary Table 2 including references 
and sample sizes. 
 We extracted summary statistics (P-values, risk alleles, ORs, and Z-scores) for 
2,558,411 common SNPs created as a reference panel from the 1000Genomes data. There 
was overlap in samples between the lung cancer study and other traits: 2,282 with blood lipids 
study, 1,959 with the BMI study and 3,179 with the T2D study. We calculated the correlation 
of two Z-score statistics for each pair of traits due to sample overlap:  rLuCa,LDL=-0.0034, r-
LuCa,TG=-0.0054,  rLuCa,HDL=0.0170, rLuCa,BMI=0.0176, rLuCa,T2D=-0.0327, rLuCa,CPD=-0.0371, and 
rLuCa,Smoker=-0.0014, suggesting that correlations due to sample overlap had a negligible 
impact on statistical inference even without explicit adjustment.  
 The analysis of lung cancer and cardiovascular risk factors included 483,841 
independent individuals. The analysis of nicotine dependence included an additional 74,053 
 individuals. The replication datasets for lung cancer consisted of 6,097 lung cancer cases and 
204,657 controls from deCODE, Harvard, Holland, and Spain; the replication for 
triglycerides and LDL-C consisted of 71,113 and 45,815 subjects, respectively from deCODE 
and Holland. Thus, we examined overall 885,576 individuals.  
 
Enrichment analysis   
We used conditional quantile-quantile (Q-Q) plots (6-9) after randomly pruning SNPs in 
linkage disequilibrium (LD) (r
2
>0.2) for visualizing the polygenic enrichment patterns of 
lung cancer by restricting to the SNP sets that showed the strongest associations in a 
secondary trait (the CVD risk factors and smoking phenotypes). In particular, a conditional 
Q-Q plot was generated for SNPs with P<1E-1, 1E-2, 1E-3, 1E-4, and 1E-5 for the secondary 
trait. In order to avoid confounding by large LD blocks, we performed a random pruning 
algorithm to compute the conditional Q-Q plot. Briefly, we defined LD blocks by an r
2
 
threshold of 0.8 and randomly selected one representative SNP from each LD block to 
compute a Q-Q plot. The final conditional Q-Q plot was generated by averaging the Q-Q 
plots from 100 random pruning steps. 
We performed permutations to test whether high-ranking SNPs for the tested risk 
factors were enriched in lung cancer GWAS.  Suppose there are 𝑁 SNPs (denoted as 𝑆) after 
LD pruning. We aimed to test whether a specific set of 𝑁1 SNPs (denoted as 𝑆1) were 
enriched in lung cancer GWAS. The standard Kolmogorov-Smirnov test or Wilcoxon rank 
sum test was not sensitive to capture the deviation in the tail of the Q-Q plots. Thus, we 
designed an adaptive permutation procedure to test the deviation in the tails. We calculated 
the ranks of all 𝑁 SNPs according to the association P values. We considered the top 𝛼 
proportion of SNPs in 𝑆1 and calculated the total number of ranks of these SNPs, denoted as 
(𝛼). We performed permutations to approximate the statistical significance of 𝑇(𝛼) as 𝑝(𝛼). 
Because the test was sensitive to the choice of 𝛼, we chose a series of 𝛼 values (𝛼1, ⋯ , 𝛼𝑚) 
and derived the corresponding P-values (𝑝(𝛼1), ⋯ , 𝑝(𝛼𝑚)). The overall one-sided statistic 
 for testing the enrichment was defined as 𝑄 = min (𝑝(𝛼1), ⋯ , 𝑝(𝛼𝑚)) and its statistical 
significance was evaluated by permutations. In our data analysis we chose (𝛼1, 𝛼2, 𝛼3, 𝛼4) =
(0.05,0.1,0.2,0.3) and ran 10,000 permutations. 
 
Assessing cross-phenotype association by conjunction FDR 
In order to identify shared risk loci between two traits we used the conjunction false 
discovery rate (FDR), a genetic epidemiology framework based on an extension of the FDR 
into two dimensions. The conditional FDR is an extension of the standard FDR that allows 
including additional information on the p-value of the same SNP in a secondary trait 2. It is 
defined as the probability that a given SNP is null given that the p-values for trait 1 and trait 2 
are as small or smaller than the observed ones. Low values of conditional FDR can be driven 
by the first trait only. To detect SNPs associated with both traits at the same time we used the 
conjunction FDR, which is defined as the probability of being null for either trait, or for both 
traits simultaneously given that the p-values for the two traits are as small or smaller than the 
observed ones. Thus, a true discovery is only the case when a SNP is non-null for both traits 
jointly. For more information on conditional and conjunction FDR and implementation we 
refer to (6, 8, 9). We aimed to control at a conservative FDR level of 0.05 per pair-wise 
comparison. 
 It has been shown that the estimation of the FDR can be impacted by correlation among 
the summary statistics (10). In order to address LD among SNPs we performed random 
pruning. First, we defined loci by an r
2
 threshold of 0.8. Within each block we selected one 
SNP randomly by chance, where every SNP had equal chance of being selected. This random 
pruning procedure was repeated 100 times and the final computation of the empirical 
distribution was averaged over the 100 pruning procedures. Thus, the impact of large LD 
blocks was reduced on the estimation of the FDR.  
 
eQTL in lung tissue 
To identify expression quantitative trait loci we first used data from an analysis of genotype 
 and matched expression data from the Genotype-Tissue Expression Consortium (GTEx) 
(11)of n=111 healthy lung tissue samples. Additionally, we performed an analysis of 
genotype and matched expression data on healthy lung tissue in a study of n=1, 111 
individuals using methodology previously described by Hao et al.(12). 
 
meQTL in lung tissue 
To identify methylation quantitative trait loci (meQTL) we applied a methodological 
approach on genotype and matched methylation data on n=210 non-tumor lung tissue samples 
as described previously by Shi et al.,(13), and in addition applied that analytical approach to a 
second dataset of non-tumor lung tissue samples obtained from The Cancer Genome Atlas 
(TCGA) lung cancer initiative (14). 
 
Chromatin-level annotation 
Publically available chromatin immunoprecipitation (ChIP)-seq data from the ENCODE and 
ROADMAP consortiums was used to determine relationship between SNPs and chromatin 
state in small airway epithelial cells (SAEC), adipocytes, and the A549 lung adenocarcinoma 
cell line, using the UCSC Genome browser, version hg19. Histone marks relating to active 
promoters were visualized with BigWig density tracks to determine if the identified loci were 
functionally active in the given cell types. Publically available ChIP-seq data on transcription 
factor binding was displayed using the UCSC genome browser.  
To fully examine DNA methylation in the region surrounding the SNPs, we 
examined whole genome bisulfite sequencing (WGBS) data that we had obtained from 
purified primary alveolar epithelial cells (AEC) obtained as previously described (15, 16). 
Libraries were plated using the Illumina cBot and run on the Hi-Seq 2000 according to 
manufacturer’s instructions using HSCS v 1.5.15.1. Rep 1 underwent Paired End 100 cycling; 
rep 2 underwent Paired End 75 cycling. Image analysis and base calling were carried out 
using RTA 1.13.48.0, deconvolution and fastq file generation was carried out using 
CASAVA_v1.7.1a5. Alignment to the genome was carried out using bsmap V 2.5. Aligned 
 .bam files were visualized using IGViewer V2.3.40 (Broad Institute, Cambridge MA) with 
alignments colored by Bisulfite mode “CG”. AEC WGBS has been made publically available 
through GEO record GSE65319 along with complete sample preparation description. 
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 Supplementary Figures 
 
Supplementary Figure 1.  Conditional Q-Q plots: LuCa | further CVD factors 
and smoking traits  
 
‘Conditional Q-Q plot’ of theoretical vs empirical -log10 p-values (corrected for genomic 
control 𝜆) in lung cancer (LuCa) below the standard GWAS threshold of -log10 p-values 
equal to 7.3 (equals p-values above 5 x 10
-8
) as a function of statistical significance of 
association with (A) HDL cholesterol (HDL-C), (B) body mass index (BMI), (C) type 2 
diabetes (T2D), (D) cigarettes per day (CPD), and (E) ever versus never smoking 
(SMOKER), at the level of p < 1, p <0.1, p < 0.01, p < 0.001, p<1.00x10-4, p<1.00x10-5 
respectively. Dotted lines indicate the theoretical line in case of no association. For the 
analysis of CPD we removed SNPs mapping to the nicotinic acetylcholine receptors 
(chr15:78,686,690-79,231,478) to exclude this well-established pleiotropic locus between 
LuCa and CPD. All statistical tests were two-sided. 
 
  
 Supplementary Figure 2.  Local Manhattan plot for cross-phenotype association 
of locus 6p22.1 between lung cancer and triglycerides (TG); top shared variant 
rs6904596 
 
On display are the log10 p-values for the association of SNPs with lung cancer (upper panel) 
and TG (lower panel) based on the SNPs genomic position. All variants with a shared 
association between lung cancer and TG (conjunction FDR < 0.05) are symbolized with 
diamonds. The leading variant for lung cancer (rs7749305) is symbolized with a triangle (top 
up) and the leading variant (rs9295740) for TG with a triangle top down. rs7749305 was not 
included in the Global Lipid Consortium GWAS. Linkage disequilibrium (LD) based on 
HapMap v.3 in Caucasians is color-coded: variants with r
2
=1 with the lead variant rs6904596 
are colored in red, 0.8=<r
2
<1 are colored in violet, and 0.5=<r
2
<0.8 are colored in blue. 
  
 Supplementary Figure 3.  Local Manhattan plot for cross-phenotype association 
of locus 1q22 between lung cancer and triglycerides (TG); top shared variant 
rs2066981 
 
On display are the log10 p-values for the association of SNPs with lung cancer (upper panel) 
and TG (lower panel) based on the SNPs genomic position. All variants with a shared 
association between lung cancer and TG (conjunction FDR < 0.05) are symbolized with 
diamonds. The leading variant for lung cancer (rs914615) is symbolized with a triangle (top 
up) and the leading variant for TG was the conjunction top variant rs2066981. Linkage 
disequilibrium (LD) based on HapMap v.3 in Caucasians is color-coded: variants with r
2
=1 
with the lead variant rs2066981 are colored in red, 0.8=<r
2
<1 are colored in violet, and 
0.5=<r
2
<0.8 are colored in blue. 
 
  
 Supplementary Figure 4.  Local Manhattan plot for cross-phenotype association 
of locus 6p22.2 between lung cancer and high-density lipoprotein (HDL); top 
shared variant rs9393692 
 
On display are the log10 p-values for the association of SNPs with lung cancer (upper panel) 
and HDL (lower panel) based on the SNPs genomic position. All variants with a shared 
association between lung cancer and HDL (conjunction FDR < 0.05) are symbolized with 
diamonds. The leading variant for lung cancer (rs3999544) is symbolized with a triangle (top 
up) and the leading variant (rs9358913) for HDL with a triangle top down. Linkage 
disequilibrium (LD) based on HapMap v.3 in Caucasians is color-coded: variants with r
2
=1 
with the lead variant rs9393692 are colored in red, 0.8=<r
2
<1 are colored in violet, and 
0.5=<r
2
<0.8 are colored in blue. 
 
  
 Supplementary Figure 5.  Local Manhattan plot for cross-phenotype association 
of locus 11q12.2 between lung cancer and triglycerides (TG); top shared variant 
rs2851682 
 
On display are the log10 p-values for the association of SNPs with lung cancer (upper panel) 
and TG (lower panel) based on the SNPs genomic position. All variants with a shared 
association between lung cancer and TG (conjunction FDR < 0.05) are symbolized with 
diamonds. The leading variant for lung cancer is the conjunction variant rs2851682; the 
leading variant for TG (rs1535) is symbolized with a triangle top down. Linkage 
disequilibrium (LD) based on HapMap v.3 in Caucasians is color-coded: variants with r
2
=1 
with the lead variant rs2851682 are colored in red, 0.8=<r
2
<1 are colored in violet, and 
0.5=<r
2
<0.8 are colored in blue. 
  
 Supplementary Figure 6.  Local Manhattan plot for cross-phenotype association 
of locus 15q15.2 between lung cancer and triglycerides (TG); top shared variant 
rs554001 
 
On display are the log10 p-values for the association of SNPs with lung cancer (upper panel) 
and TG (lower panel) based on the SNPs genomic position. All variants with a shared 
association between lung cancer and TG (conjunction FDR < 0.05) are symbolized with 
diamonds. The leading variant for lung cancer is the conjunction variant rs554001; the 
leading variant for TG (rs580469) is symbolized with a triangle top down. Linkage 
disequilibrium (LD) based on HapMap v.3 in Caucasians is color-coded: variants with r
2
=1 
with the lead variant rs554001 are colored in red, 0.8=<r
2
<1 are colored in violet, and 
0.5=<r
2
<0.8 are colored in blue. 
 
  
 Supplementary Figure 7. rs7749305 lies in a regulatory element in lung and fat 
tissues/cell lines.  
 
Epigenetic annotation of rs7749305 on chromosome 6 in a frame of 10KB up and 
downstream using peaks from tissues relevant for lung cancer and blood lipid traits. At the 
top, the UCSC Genome browser image shows the ZNF184 locus and to the right below that 
the position of rs7749305. Below that we show: in small airway epithelial cells (SAEC), 
DNase hypersensitive sites; in adipocytes, duplicate lanes of ChIP-seq marks for H3K4me1, 
H3K4me3 and H3K9ac; in A459 cells, duplicate DNase hypersensitive sites, and ChIP-seq 
marks for H3K4me1, H3k4me3 and H3K9ac; and in our own human alveolar epithelial cells 
(AEC), duplicate whole genome bisulfite sequencing (WGBS; red=methylated CpGs, 
blue=unmethylated CpGs). At the bottom, the position of the SNP and its effect on ATF3 and 
HIF1A binding sites is indicated.  
 
  
 Supplementary Tables 
 
Supplementary Table 1.  TRICL lung cancer studies in the discovery dataset* 
 
Study 
All Squamous cell carcinoma Adenocarcinoma 
cases controls cases controls cases controls 
UK 1952 5200 611 5200 465 5200 
MDACC 1150 1134 306 1134 619 1134 
IARC 2533 3791 911 2968 517 2824 
NCI 5713 5736 1447 5736 1841 5736 
SLRI 331 499 50 499 90 499 
GERMAN 481 478 97 478 186 478 
Total 12160 16838 3422 16015 3718 15871 
* UK = Institute of Cancer Research, London; MADACC = University of Texas MD 
Anderson Cancer Center; IARC = International Agency for Research on Cancer; NCI = 
National Cancer Institute; SLRI = Samuel Lunenfeld Research Institute, Toronto; GERMAN 
= German Cancer Research Center (DKFZ). 
 
  
 Supplementary Table 2.  Discovery dataset 
 
Disease/Trait N # SNPs Reference 
Lung Cancer 
(LgCa)  
28,998 2,433,836 
Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in 
BRCA2 and CHEK2 affect risk of lung cancer; Nat Genet 2014; 46, 
736–741_DETAILS IN SUPPL.Table 2 
Body Mass 
Index (BMI) 
123,865 2,400,377 
Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 
249,796 individuals reveal 18 new loci associated with body mass 
index. Nat Genet 2010;42:937-48. 
Type 2 Diabetes 
(TD2) 
149,821 94,012 
 Morris AP, Voight BF, Teslovich TM, et al. Large-scale 
association analysis provides insights into the genetic architecture 
and pathophysiology of type 2 diabetes. Nature genetics 2012; 44: 
981-90; http://diagram-consortium.org 
Low density 
lipoprotein 
(LDL) 
188,577 2,491,989 
 
 
Willer CJ, Schmidt EM, et al. Discovery and refinement of loci 
associated with lipid levels. Nat Genet 2013:45, 1274–1283; 
http://csg.sph.umich.edu//abecasis/public/lipids2013/                          
Triglycerides 
(TG) 
188,577 
        
2,487,152 
High density 
lipoprotein 
(HDL) 
188,577 
        
2,492,237 
Total lipid traits 
contributing to 
the meta-
analysis 
491,261 
 
Total lung 
cancer and 
CVD traits' 
subjects 
removing the 
overlapping 
subjects 
483,841 
Cigarettes per 
day (CPD) 
74,053 2,397,337 
The Tobacco and Genetics Consortium Genome-wide meta-
analyses identify multiple loci associated with smoking behavior. 
Nat Genet 2010: 42, 441–447 
Total subjects 
including those 
in CPD analysis 
557,894  
eQTL lung  1,111  
Hao, K, Bosse, Y, Nickle, DC, et al. Lung eQTLs to help reveal the 
molecular underpinnings of asthma. (2012) PLoS Genet, 8(11), 
e1003029. doi: 10.1371/journal.pgen.1003029 
meQTL lung 244  
Shi, J, Marconett, CN, Duan, J, et al. Characterizing the genetic 
basis of methylome diversity in histologically normal human lung 
tissue. Nat Commun (2014) 5, 3365 
 
 
  
 Supplementary Table 3.  Testing for enrichment by permutation* 
 
Enrichment 
p-value† 
HDL LDL TG BMI T2D CPD SMOKER 
p<0.001 0.15 0.001 <0.0001 0.36 0.28 0.46 0.10 
p<0.0001 0.06 <0.0001 <0.0001 0.37 0.35 0.55 0.55 
* Smoking phenotypes analysis excluded the chrom. 15q25 locus (chr15:78686690-
79231478).  LDL = Low density lipoprotein cholesterol; HDL = High density lipoprotein 
cholesterol; TG = Triglycerides; BMI = Body mass index; T2D = Type 2 Diabetes; CPD = 
Cigarettes per day; SMOKER = ever vs. never smoker. 
† Permutation test (one-sided) for enrichment, for further details see supplementary material.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 4.  Summary data for cross-phenotype associated loci for lung cancer and lipid traits*  
 
SNP Gene Band Ref. 
A. 
Alt. 
A. 
MAF  LuCa&LDL LuCa&TG LuCa&HDL p_LuCa† p_LDL† p_TG† p_HDL†  z_LuCa‡ z_LDL‡ z_TG‡ z_HDL‡ 
rs2066981 THBS3 1q22 G A 0.57 2.70E-01 3.17E-02 6.51E-01 3.86E-06 7.40E-03 4.85E-04 0.04 4.62E+00 -2.68E+00 
-
3.49E+00 2.01E+00 
rs9393692 
HIST1H2B
I 6p22.2 A G 0.57 6.07E-01 1.00E+00 3.64E-02 2.03E-05 0.05. 0.81 6.31E-05 -4.26E+00 -1.95E+00 2.46E-01 -4.00E+00 
rs6904596 § ZNF184 6p22.1 A G 0.08 9.33E-01 1.24E-02 2.59E-02 8.70E-06 0.6.3 7.79E-06 3.19E-04 4.45E+00 -4.74E-01 4.47E+00 3.60E+00 
rs2851682‖ MYRF 11q12.2 A G 0.11 2.91E-02 2.49E-02 4.13E-02 3.23E-05 5.99E-18 1.89E-15 1.13E-09 -4.16E+00 8.63E+00 
-
7.95E+00 6.09E+00 
rs554001
¶
 TGM5 15q15.2 G A 0.33 1.00E+00 4.49E-02 3.65E-01 7.98E-05 0.8.6 8.63E-04 0.01 -3.95E+00 1.74E-01 
-
3.33E+00 2.49E+00 
 
*Independent genetic loci (r2 < 0.2) with a conjunction FDR < 0.05 in both lung cancer (LuCa) and in low density lipoprotein  (LDL); in both lung cancer and in 
triglycerides (TG); or in both lung cancer and in high density lipoprotein  (HDL) after removing the major histocompatibility complex (MHC) on chromosome 6 
(genomic position (hg 19): chr6:29528318-33373649).  The table shows the SNPs with the strongest association in each LD block based on the minimum conjunction 
FDR (LuCa&LDL, LuCa&TG, LuCa&HDL). LuCa = Lung cancer; LDL = Low density lipoprotein  cholesterol; HDL = High density lipoprotein cholesterol; TG = 
Triglycerides. 
†
 p = SNP association test P-value (two-sided) from a two-sided Wald test 
‡
z =   SNP effect size (z-score) with respect to reference allele  
§Only this locus has been replicated in both lung cancer and lipid traits (triglycerides)  
‖This locus was previously identified in association with lipid traits (Global Lipids Genetics Consortium et al. Nat Genet 45, 1274-83, 2013) 
¶
This locus was previously identified in association with lung cancer risk (Rafnar, T. et al. Cancer Res 71, 1356-61, 2011) 
 
 
 Supplementary Table 5.  Sensitivity analysis: p-values for conjunction FDR for 
lung cancer and triglyceride levels of the 6p22.1 locus using different r
2 
thresholds 
for pruning SNPs in LD 
 
r
2
 0.8 0.7 0.6 0.5 0.4 0.3 0.2 
conjunction 
FDR  
1.24E-02  1.01E-02 8.86E-03  6.81E-03  5.77E-03 4.16E-03   2.78E-03 
 
 
 
  
 Supplementary Table 6.  Replication dataset* 
 
Study Phenotype Cases Controls 
Lung Cancer    
DeCODE    
 
Lung cancer 3865 196658 
Lung 
adenocarcinoma 
1434 198663 
Lung squamous 
cell carcinoma 
784 171059 
Harvard    
 
Lung cancer 984 970 
Lung 
adenocarcinoma 
597 970 
Lung squamous 
cell carcinoma 
216 970 
Holland    
 
Lung cancer 687 5158 
Lung 
adenocarcinoma 
250 5158 
Lung squamous 
cell carcinoma 
251 5158 
Spain    
 
Lung cancer 561 1871 
Lung 
adenocarcinoma 
97 1871 
Lung squamous 
cell carcinoma 
167 1871 
Total  6097 204657 
Study  Phenotype Subjects 
Lipid traits   
deCODE LDL* 40724 
 Triglycerides 66027 
Holland LDL* 5091 
*LDL= Low density lipoprotein cholesterol 
 
  
 Supplementary Table 7.  Summary data for genetic loci and lead SNP 
rs6904596 with reference allele A and alternative allele G at 6p22.1 in lung 
adenocarcinoma and squamous cell carcinoma.  
 
Study OR 95% CI p-value* 
Adenocarcinoma    
TRICL 1.05 (0.95,1.15) 0.354 
DECODE 1.09 (0.93,1.29) 0.293 
Harvard 1.14 (0.87,1.50) 0.343 
Dutch 1.22 (0.93,1.61) 0.15 
Spain 0.96 (0.58,1.60) 0.89 
Replication 1.12 (0.99,1.26) 0.07 
Combined 1.08 (1.00,1.17) 0.061 
p for heterogeneity†  0.85 
Squamous cell carcinoma    
TRICL 1.21 (1.11,1.33) 4.50E-05 
DECODE 1.11 (0.88,1.38) 0.38 
Harvard 1.15 (0.78,1.71) 0.48 
Holland 1.05 (0.79,1.40) 0.73 
Spain 1.18 (0.81,1.71) 0.4 
Replication 1.11 (0.95,1.29) 0.18 
Combined 1.18 (1.09,1.28) 2.80E-05 
p for heterogeneity†   0.90 
* P-values were derived from a two-sided Wald test. The reference group for the odds 
ratio (OR)  in the lung cancer study were healthy controls without lung cancer. 
CI=confidence interval. 
† Heterogeneity of effect size across studies was evaluated using the Cochran’s Q 
statistic. The test is defined as one-sided. 
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